Wieland S, Fischette C T, Lucki I
Department of Psychiatry, University of Pennsylvania, Philadelphia 19104.
Neuropharmacology. 1993 Jun;32(6):561-73. doi: 10.1016/0028-3908(93)90052-5.
The effects of acute and chronic treatment of rats with the tricyclic antidepressant imipramine, the 5-HT1A receptor partial agonist tandospirone, or its metabolite 1-PP were compared on behavioral responses produced by the activation of 5-HT receptors and on brain monoamine receptors. The behaviors examined were the 5-HT behavioral syndrome elicited by the 5-HT1A receptor agonist 8-OH-DPAT and the head shake response produced by the 5-HT2 receptor agonist DOB. Drug treatments were administered either by subcutaneous infusion from implanted minipumps or by repeated injection and the effects of chronic drug treatment were assessed when the drug was present and absent at the time of testing. The infusion of tandospirone blocked elicitation of the 5-HT behavioral syndrome when tested after 1 or 14 days of drug treatment (drug present) and 24 hr after the drug was withdrawn (drug absent). When administered by injection, tandospirone blocked the production of the 5-HT syndrome 1 hr (drug present), but not 24 hr (drug absent), following either 1 day or 14 days of drug treatment. Chronic infusion of imipramine did not alter the 5-HT syndrome. Chronic, but not acute, injections of imipramine blocked the 5-HT syndrome when tested 1 hr but not 24 hr, after the final injection. Treatment with 1-PP did not alter the 5-HT syndrome. The head shake response was attenuated by acute and chronic injection of tandospirone either 1 or 24 hr after treatment, although chronic infusion of tandospirone did not alter this behavior. Head shaking was attenuated by the infusion and injection of imipramine after acute treatment, chronic treatment, or following drug withdrawal. Chronic injection of 1-PP also inhibited the head shake response 24 hr after injection, although 1-PP was ineffective at all other times and when given by infusion. The density of hippocampal 5-HT1A receptors was unaltered by the chronic drug treatments. 5-HT2 receptor density in frontal cortex was reduced by the chronic infusion of either tandospirone, imipramine, and 1-PP, but only by chronic injections of imipramine. The density of cortical beta-adrenergic receptors was reduced following chronic imipramine injections or infusion. The results suggest that both tandospirone and imipramine may regulate 5-HT-mediated responses and 5-HT2 receptor density, which may contribute to their efficacy as antidepressants, although their effects were dependent upon the method of administration and may involve different neuropharmacological mechanisms.
比较了用三环类抗抑郁药丙咪嗪、5-HT1A受体部分激动剂坦度螺酮或其代谢物1-PP对大鼠进行急性和慢性治疗后,5-HT受体激活产生的行为反应以及脑单胺受体的影响。所检测的行为包括5-HT1A受体激动剂8-OH-DPAT引发的5-HT行为综合征以及5-HT2受体激动剂DOB产生的摇头反应。药物治疗通过植入微型泵皮下输注或重复注射进行,并且在测试时药物存在和不存在的情况下评估慢性药物治疗的效果。在药物治疗1天或14天后(药物存在)以及停药24小时后(药物不存在)进行测试时,输注坦度螺酮可阻断5-HT行为综合征的引发。当通过注射给药时,在药物治疗1天或14天后,坦度螺酮在1小时(药物存在)时可阻断5-HT综合征的产生,但在24小时(药物不存在)时则不能。慢性输注丙咪嗪不会改变5-HT综合征。慢性(而非急性)注射丙咪嗪后,在最后一次注射1小时后(而非24小时后)进行测试时可阻断5-HT综合征。用1-PP治疗不会改变5-HT综合征。在治疗后1小时或24小时,急性和慢性注射坦度螺酮均可减弱摇头反应,尽管慢性输注坦度螺酮不会改变这种行为。在急性治疗、慢性治疗或停药后,输注和注射丙咪嗪均可减弱摇头反应。慢性注射1-PP在注射后24小时也可抑制摇头反应,尽管1-PP在所有其他时间以及通过输注给药时均无效。慢性药物治疗未改变海马5-HT1A受体的密度。额叶皮质中5-HT2受体密度因慢性输注坦度螺酮、丙咪嗪和1-PP而降低,但仅因慢性注射丙咪嗪而降低。慢性注射或输注丙咪嗪后,皮质β-肾上腺素能受体密度降低。结果表明,坦度螺酮和丙咪嗪均可调节5-HT介导的反应和5-HT2受体密度,这可能有助于它们作为抗抑郁药的疗效,尽管它们的作用取决于给药方法,并且可能涉及不同的神经药理学机制。